Angiogenesis and hematological malignancies

Hematology

Volumn 10, Issue 1, 2005, Pages 11-24

  Lim, Soon Thye ^a,b   Levine, Alexandra M ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Angiogenesis; Anti angiogenic therapies; Endothelial growth factors; Hematoligx malignancy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ENDOSTATIN; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERFERON; LENALIDOMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; MONOCLONAL ANTIBODY LM 609; ONCOPROTEIN; PACLITAXEL; PRINOMASTAT; SEMAXANIB; TANOMASTAT; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VEGLIN; VINBLASTINE;

ANGIOGENESIS; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG MECHANISM; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; NEUROPATHY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; TREATMENT INDICATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; HEMATOLOGIC NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23244453918     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330400018409     Document Type: Review

References (151)

1. Folkman, J. (1971) "Tumor angiogenesis: therapeutic implications", N. Engl. J. Med. 21, 1182-1186.
2. Bussolino, F., Mantovani, A. and Persico, G. (1997) "Molecular mechanisms of blood vessel formation", Trends Biochem. Sci. 22, 251-256.
3. Gleadle, J.M. and Ratcliffe, P.J. (1998) "Hypoxia and the regulation of gene expression", Mol. Med. Today 3, 122-129.
4. Ferrara, N., Carver-Moore, K., Chen, H., et al. (1996) "Heterozygous enbryonic lethality induced by targeted inactivation of the VEGF gene", Nature 6573, 438-442.
5. Tischer, E., Mitchell, R., Hartman, T., et al. (1991) "The human gene for vascular endothelial growth factor", J. Biol. Chem. 266, 11947-11954.
6. Houck, K.A., Ferrara, N., Winer, J., et al. (1991) "The vascular endothelial growth factor family: identificatieon of a fourth molecular species and characterization of alternative splicing of RNA", Mol. Endocrinol. 5, 1806-1814.
7. Olofsson, B., Pajusola, K., Kaipainen, A., et al. (1996) "Vascular endothelial growth factor B, a novel growth factor for endothelial cells", Proc. Natl Acad. Sci. USA 93, 2576-2581.
8. Kukk, E., Lymboussaki, A., Taira, S., et al. (1996) VEGF-C Receptor Binding and Pattern of Expression with VEGFR-3 Suggests a Role in Lymphatic Vascular Development Vol. 122, pp 3829-3837.
9. Kaipainen, A., Korhonen, J., Mustonen, T., et al. (1995) "Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development", Proc. Natl Acad. Sci. USA 92, 3566-3570.
10. Joukov, V., Sorsa, T., Kumar, V., et al. (1997) "Proteolytic processing regulates receptor specificity and activity of VEGF-C", EMBO J. 16, 3898-3911.
11. Achen, M.G., Jeltsch, M., Kukk, E., et al. (1998) "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)", Proc. Natl Acad. Sci. USA. 95, 548-553.
12. Maglione, D., Guerriero, V., Viglietto, G., et al. (1991) "Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor", Proc. Natl Acad. Sci. USA 88, 9267-9271.
13. Veikkola, T., Karkkainen, M., Claesson-Welsh, L., et al. (2000) "Regulation of angiogenesis via vascular endothelial growth factor receptors", Cancer Res. 2, 203-212.
14. Aprelikova, O., Pajusola, K., Partanen, J., et al. (1992) "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter", Cancer Res. 3, 746-748.
15. Millauer, B., Wizigmann-Voos, S., Schnurch, H., et al. (1993) "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis", Cell 72, 835-846.
16. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., et al. (1994) "Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor", J. Biol. Chem. 269, 26988-26995.
17. Soker, S., Takashima, S., Miao, H.Q., et al. (1998) "Neuropilin-1 is expressed by endothlelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor", Cell 92, 736-745.
18. Takahashi, T., Ueno, H., Shibuya, M., et al. (1999) "VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK- MAP kinase pathway for DNA synthesis in primary endothelial cells", Oncogene 18, 2221-2230.
19. Meadows, K.N., Bryant, P. and Pumiglia, K.M. (2001) "VEGF-induction of the angiogenic phenotype requires Ras activation", J. Biol. Chem. 52, 49289-49298.
20. Wu, W., Shu, X., Hovsepyan, H., et al. (2003) "VEGF receptor expression and signaling in human bladder tumors", Oncogene 22, 3361-3370.
21. Shu, X., Wu, W., Mosteller, R.D., et al. (2002) "Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases", Mol. Cell Biol. 22, 7758-7768.
22. Gerber, H.P., McMurtrey, A., Kowalski, J., et al. (1998) "Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation", J. Biol. Chem. 273, 30336-30343.
23. Eriksson, A., Cao, R., Roy, J., et al. (2003) "Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability", Circulation 107, 1532-1538.
24. Rousseau, S., Houle, F., Landry, J., et al. (1997) "MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells", Oncogene 15, 2169-2177.
25. Qi, J.H. and Claesson-Welsh, L. (2001) "VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase", Exp. Cell. Res. 263, 173-182.
26. Dankbar, B., Padró, T., Leo, R., et al. (2000) "Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma", Blood 95, 2630-2636.
27. Fiedler, W., Graeven, U., Ergun, S., et al. (1997) "Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia", Blood 89, 1870-1875.
28. Davis, S., Aldrich, T.H., Jones, P.F., et al. (1996) "Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning", Cell 87, 1161-1169.
29. Suri, C., Jones, P.F., Patan, S., Bartunkova, S., et al. (1996) "Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis", Cell. 87, 1171-1180.
30. Maisonpierre, P.C., Suri, C., Jones, P.F., et al. (1997) "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis", Science 277, 55-60.
31. Moore, B.B., Keane, M.P., Addison, C.L., et al. (1998) "CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family", J. Investig. Med. 46, 113-120.
32. Brown, N.S. and Bicknell, R. (1998) "Thymidine phosphorylase, 2-deoxy-d-ribose and angiogenesis", Biochem. J. 334, 1-8.
33. Chiarugi, V, Magnelli, L. and Gallo, O. (1998) "Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review)", Int. J. Mol. Med. 2, 715-719.
34. Presta, M., Moscatelli, D., Joseph-Silverstein, J., et al. (1986) "Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration", Mol. Cell. Biol. 6, 4060-4066.
35. Hata, Y., Rook, S.L., Aiello, L.P., et al. (1999) "Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway", Diabetes 48, 1145-1155.
36. Bussolino, F., Albini, A., Camussi, G., et al. (1996) "Role of soluble mediators in angiogenesis", Eur. J. Cancer 32A, 2401-2412.
37. Holder, N. and Klein, R. (1999) "Eph receptors and ephrins: effectors of morphogenesis", Development 26, 2033-2044.
38. Wang, H.U., Chen, Z.F. and Anderson, D.J. (1998) "Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4", Cell 93, 741-7453.
39. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., et al. (1995) "Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis", Cancer Res. 55, 4575-4580.
40. Iliopoulos, O., Levy, A.P., Jiang, C., et al. (1993) "Negative regulation of hypoxia-inducible genes by the von Hippel Lindau protein", Proc. Natl Acad. Sci. USA 93, 10595-10599.
41. Vanmeir, E.G., Polverini, P.J., Chazin, V.R., et al. (1994) "Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells", Nat. Genet. 8, 171-176.
42. Siemeister, G., Weindel, K., Mohrs, K., et al. (1996) "Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein", Cancer Res. 56, 2299-2301.
43. Wang, Y.Q., Luk, J.M., Ikeda, K., et al. (2004) "Regulatory role of vHL/HIF-1 alpha in hypoxia-induced VEGF production in hepatic stellate cells", Biochem. Biophys. Res. Commun. 317, 358-362.
44. Choi, K.S., Bae, M.K., Jeong, J.W., et al. (2003) "Hypoxia-induced angiogenesis during carcinogenesis", J. Biochem. Mol. Biol. 36, 120-127.
45. Satake, S., Kuzuya, M., Miura, H., et al. (1998) "Upregulation of vascular endothelial growth factor in response to glucose deprivation", Biol. Cell 2, 161-168.
46. Shweiki, D., Neeman, M., Itin, A., et al. (1995) "Induction of vascular endothelial growth factor expression by hypoxia and by glucose de.ciency in multicell spheroids: Implications for tumor angiogenesis", Proc. Natl Acad. Sci. USA 92, 768-772.
47. Carmeliet, P. and Jain, R.K. (2000) "Angiogenesis in cancer and other diseases", Nature 407, 249-257.
48. Tsujii, M., Kawano, S., Tsuji, S., et al. (1998) "Cycloxigenase regulates angiogenesis induced by colon cancer cells", Cell 93, 705-716.
49. Coussens, L.M., Raymond, W.W., Bergers, G., et al. (1999) "Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis", Genes Dev. 13, 1382-1387.
50. Mignatti, P. and Rifkin, D.B. (1996) "Plasminogen activators and matrix metalloproteinases in angiogenesis", Enzyme Protein 49, 117-137.
51. Bikfalvi, A., Klein, S., Pintucci, G. and Rifkin, D.B. (1997) "The roles of proteases in angiogenesis", In: Bicknell, R., Lewis, C.E. and Ferrara, N., eds, Tumor Angiogenesis (Oxford University press), pp 115-124.
52. Murphy, H., Stanton, S., Cowell, G., et al., Mechanisms for pro matrix metalloproteinase activation. APMIS; 107: 38-44.
53. Bischoff, J. (1997) "Cell adhesion and angiogenesis", J. Clin. Invest. 100, S37-S39.
54. Eliceiri, B.P. and Cheresh, D.A. (1999) "The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development", J. Clin. Invest. 103, 1227-1230.
55. Carmeliet, P., Lampugnani, M.G., Moons, L., et al. (1999) "Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis", Cell 98, 147-157.
56. Tolsma, S.S., Volpert, O.V., Good, D.J., et al. (1993) "Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity", J. Cell Biol. 122, 497-511.
57. Dvorak, H.F. and Gresser, I. (1989) "Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice", J. Natl Cancer Inst. 81, 497-502.
58. O'Reilly, M.S., Holmgren, L., Shing, Y., et al. (1994) "Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma", Cell 79, 315-328.
59. O'Reilly, M.S., Boehm, T., Shing, Y., et al. (1997) "Endostatin: an endogenous inhibitor of angiogenesis and tumor growth", Cell 88, 277-285.
60. O'Reilly, M.S., Pirie-Shepherd, S., Lane, W.S., et al. (1999) "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin", Science 285, 1926-1928.
61. Stellmach, V., Volpert, O.V., Crawford, S.E., et al. (1996) "Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts", Eur. J. Cancer 32A, 2394-2400.
62. Dias, S., Hattori, K., Zhu, Z., et al. (2000) "Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration", J. Clin. Invest. 106, 511-521.
63. Dias, S., Shmelkov, S.V., Lam, G., et al. (2002) "VEGF 165 promotes survival of leukemic cells by HSP90-mediated induction of BCl-2 expression and apoptosis inhibition", Blood 99, 2532-2540.
64. Padro, T., Ruiz, S., Bieker, R., et al. (2000) "Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia", Blood 95, 2637-2644.
65. Aguayo, A., Estey, E., Kantarjian, H., et al. (1999) "Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia", Blood 94, 3717-3721.
66. Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., et al. (1997) "Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia", Am. J. Pathol. 150, 815-821.
67. Koomagi, R., Zintl, F., Sauerbrey, A., et al. (2001) "Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real time quantitative polymerase chain reaction", Clin. Cancer Res. 7, 3381-3384.
68. Kini, A.R., Kay, N.E. and Peterson, L.C. (2000) "Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia", Leukemia 14, 1414-1418.
69. Chen, H., Treweeke, A.T., West, D.C., et al. (2000) "In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukmia cells", Blood 96, 3181-3187.
70. Molica, S., Vitelli, G., Levato, D., et al. (1999) "Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia", Br. J. Haematol. 107, 605-610.
71. Aguayo, A., O'Brien, S., Keating, M., et al. (2000) "Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia", Blood 96, 768-770.
72. Kamiguti, A.S., Lee, E.S., Till, K.J., et al. (2004) "The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia", Br. J. Haematol. 125, 128-140.
73. Aguayo, A., Kantarjian, H., Manshouri, T., et al. (2000) "Angiogenesis in acute and chornic leukemias and myelodysplastic syndromes", Blood 96, 2240-2245.
74. Verstovsek, S., Kantarjian, H., Manshouri, T, et al. (2002) "Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia", Blood 99, 2265-2267.
75. Verstovsek, S., Lunin, S., Kantarjian, H., et al. (2003) "Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia", Leuk. Res. 27, 661-669.
76. Ribatti, D., Vacca, A., Marzullo, A., et al. (2000) "Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B cell non-Hodgkin's lymphomas", Int.J. Cancer 85, 171-175.
77. Foss, H.D., Araujo, I., Demel, G., et al. (1997) "Expression of vascular endothelial growth factor in lymphomas and Castleman's disease", J. Pathol. 183, 44-50.
78. Salven, P., Orpana, A., Teerenhovi, L., et al. (2000) "Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single institution study of 200 patients", Blood 96, 3712-3718.
79. Niitsu, N., Okamoto, M., Nakamine, H., et al. (2002) "Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin 6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma", Eur. J. Haematol. 68, 91-100.
80. Kuittinen, O., Apaja-Sarkkinen, M. and Turpeenniemi-Hujanen, T. (2003) "Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas", Eur. J. Haematol. 71, 91-99.
81. Vacca, A., Ribatti, D., Roncali, L., et al. (1994) "Bone marrow angiogenesis and progression in multiple myeloma", Br. J. Haematol. 87, 503-508.
82. Munshi, N.C. and Wilson, C. (2001) "Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis", Semin. Oncol. 28, 565-569.
83. Rajkumar, S.V., Leong, T., Toche, P.C., et al. (2000) "Prognostic value of bone marrow angiogenesis in multiple myeloma", Clin. Cancer Res. 6, 3111-3116.
84. Sezer, O., Niemoller, K., Kaufmann, O., et al. (2001) "Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy", Br. J. Haematol. 66, 238-244.
85. Di Raimondo, F., Azzaro, M.P., Palumbo, G., et al. (2000) "Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood", Hematologica 85, 800-805.
86. Rajkumar, S.V, Fonseca, R., Witzig, T.E., et al. (1999) "Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma", Leukemia 3, 469-472.
87. Bellamy, W.T., Richter, L., Frutiger, Y., et al. (1999) "Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies", Cancer Res. 59, 728-733.
88. Cohen, T., Nahari, D., Cerem, L.W., et al. (1996) "Interleukin 6 induces the expression of vascular endothelial growth factor", J. Biol. Chem. 271, 736-741.
89. Albini, A., Soldi, R., Giunciuglio, D., et al. (1996) "The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells", Nat. Med. 2, 1371-1375.
90. Masood, R., Cai, J., Zheng, T., et al. (2001) "P.S. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors", Blood 98, 1904-1913.
91. Masood, R., Cai, J., Zheng, T, et al. (1997) "Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor of AIDS-Kaposi sarcoma", Proc. Natl Acad. Sci. USA 94, 979-984.
92. Bais, C., Van Geelen, A., Eroles, P., et al. (2003) "Kaposi's sarcoma associated herpesvirus G protein coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR", Cancer Cell 3, 131-143.
93. Dezube, B.J., von Roenn, J.H., Holden-Wiltse, J., et al. (1998) "Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS clinical trial group study", J. Clin. Oncol. 16, 1444-1449.
94. Little, R.F., Wyvill, K.M., Pluda, J.M., et al. (2000) "Activity of thalidomide in AIDS related Kaposis' sarcoma", J. Clin. Oncol. 18, 2593-2602.
95. Van de Rijn, M., Hendrickson, M.R. and Rouse, R.V. (1994) "CD34 expression by gastrointestinal tract stromal tumors", Hum. Pathol. 25, 766-771.
96. Little, D., Said, J.W., Siegel, R.J., et al. (1986) "Endothelial cell markers in vascular neoplasms: an immunohistochemical study comparing FVIIIr Ag, blood group specific antigens, 6-keto PGF1 alpha and Ulex europeus 1 lectin", J. Pathol. 149, 89-95.
97. Mangi, M.H. and Layton, D.M. (1994) "The cells of human yolk sac blood island express CD34 and produce GM-CSF (Abstract)", Blood 84, 268a.
98. Brunner, G., Nguyen, H., Gabrilove, J., et al. (1993) "Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells", Blood 81, 631-638.
99. Presta, L.G., Chen, H., O'Connor, S.J., et al. (1997) "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders", Cancer Res. 57, 4593-4599.
100. Yang, J.C., Haworth, L., Sherry, R.M., et al. (2003) "A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer", N. Engl. J. Med. 349, 427-434.
101. Levine, A.M., Quinn, D.I., Gorospe, G., Lenz, H.J., et al. (2004), J. Clin. Oncol. 22(No. 145), 3008, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), (July 15 Supplement).
102. Peterson, A.C., Swiger, S., Stadler, W.M., et al. (2004) "Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma", Clin. Cancer Res. 10, 4048-4054.
103. Stadler, W.M., Cao, D., Vogelzang, N.J., et al. (2004) "Randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer", Clin. Cancer Res. 10, 3365-3370.
104. Stopeck, A., Sheldon, M., Vahedian, M., et al. (2002) "Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies", Clin. Cancer Res. 8, 2798-2805.
105. Girmens, J.F., Erginay, A., Massin, P., et al. (2003) "Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas", Am. J. Ophthalmol. 136, 194-196.
106. Fiedler, W., Mesters, R., Tinnefeld, H., et al. (2003) "A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia", Blood 102, 2763-2767.
107. Giles Giles, F.J., Stopeck, A.T., Silverman, L.R., et al. (2003) "SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes", Blood 102, 795-801.
108. Zucker, S., Cao, J. and Chen, W.T. (2000) "Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment", Oncogene 19, 6642-6650.
109. Rader, C., Popkov, M., Neves, J.A., et al. (2002) "Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody", FASEB J. 16, 2000-2002.
110. Gutheil, J.C., Campbell, T.N., Pierce, P.R., et al. (2000) "Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphav-beta3", Clin. Cancer Res. 6, 3056-3061.
111. Posey, J.A., Khazaeli, M.B., DelGrosso, A., et al. (2001) "A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer", Cancer Biother. Radiopharm. 16, 125-132.
112. Thomas, J.P., Arzoomanian, R.Z., Alberti, D., et al. (2003) "Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors", Clin. Oncol. 21, 223-231.
113. Eder, J.P., Jr., Supko, J.G., Clark, J.W., et al. (2002) "Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily", J. Clin. Oncol. 20, 3772-3784.
114. Herbst, R.S., Hess, K.R., Tran, H.T., et al. (2002) "Phase I study of recombinant human endostatin in patients with advanced solid tumors" J. Clin. Oncol. 20, 3792-3803.
115. 1 phase of the cell cycle", Cancer Res. 54, 2073-2076.
116. Noren-Nystrom, U., Eriksson, M., Eriksson, B., et al. (2003) "Antitumor activity of the angiogenesis inhibitor TNP-470 on murine lymphoma/leukemia cells in vivo and in vitro", Exp. Hematol. 31, 143-149.
117. Arora, N., Masood, R., Zheng, T., et al. (1999) "Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells", Cancer Res. 59, 183-188.
118. Olson, T.A., Mohanraj, D., Roy, S., et al. (1997) "Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate", Int. J. Cancer 73, 865-870.
119. Singhal, S., Mehta, J., Desikan, R., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", N. Engl. J. Med. 341, 1565-1571.
120. Rajkumar, S.V., Fonseca, R., Dispenzieri, A., et al. (2000) "Thalidomide in the treatment of relapsed multiple myeloma", Mayo Clin. Proc. 75, 897-901.
121. Yakoub-Agha, I., Moreau, P., Leyvraz, S., et al. (2000) "Thalidomide in patients with advanced multiple myeloma", Hematol. J. 1, 186-189.
122. Kneller, A., Raanani, P., Hardan, I., et al. (2000) "Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug", Br. J. Haematol. 108, 391-393.
123. Rajkumar, S.V., Dispenzieri, A., Fonseca, R., et al. (2001) "Thalidomide for previously untreated indolent or smoldering multiple myeloma", Leukemia 15, 1274-1276.
124. Rajkumar, S.V., Hayman, S., Gertz, M.A., et al. (2002) "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma", J. Clin. Oncol. 20, 4319-4323.
125. Rajkumar, S.V., Blood, E., Vesloe, D.H., et al. (2004) "A randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group", Proc. Am. Soc. Clin. Oncol. 23, 558, Abstract 6508.
126. Bartlett, J.B., Dredge, K. and Dalgleish, A.G. (2004) "The evolution of thalidomide and its IMiD derivatives as anticancer agents", Nat. Rev. Cancer 4, 314-322.
127. Richardson, P.G., Schlossman, R.L., Weller, E., et al. (2002) "Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma", Blood 100, 3063-3067.
128. Raza, A., Meyer, P., Dutt, D., et al. (2001) "Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes", Blood 98, 958-965.
129. Zorat, F., Shetty, V., Dutt, D., et al. (2001) "The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes", Br. J. Haematol. 115, 881-894.
130. Strupp, C., Germing, U., Aivado, M., et al. (2002) "Thalidomide for the treatment of patients with myelodysplastic syndromes", Leukemia 16, 1-6.
131. List, A.F., Kurtin, S.E., Glinsmann-Gibson, B.J., et al. (2002) "High erythropoietic remitting activity of the immunomodulatorythalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS)", Blood 100(11), 96a.
132. Jonasch, E. and Haluska, F.G. (2001) "Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities", Oncologist 6, 34-55.
133. Kirkwood, J. (2002) "Cancer immunotherapy: the interferon-alpha experience", Semin. Oncol. 29 (3 Suppl 7), 18-26, June.
134. Quesada, J.R., Hersh, E.M. and Gutterman, J.U. (1984) "Biologic therapy of hairy cell leukemia", Semin. Oncol. 11 (4 Suppl 2), 507-510, December.
135. Folkman, J. (1989) "Successful treatment of an angiogenic disease", N. Engl. J. Med. 320, 1211-1212, May 4.
136. Ezekowitz, R.A., Mulliken, J.B. and Folkman, J. (1992) "Interferon alfa-2a therapy for life-threatening hemangiomas of infancy", N. Engl. J. Med. 326, 1456-1463.
137. Takahashi, K., Mulliken, J.B., Kozakewich, H.P., et al. (1994) "Cellular markers that distinguish the phases of hemangioma during infancy and childhood", J. Clin. Invest. 93, 2357-2364.
138. Singh, R.K., Gutman, M., Bucana, C.D., et al. (1995) "Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas", Proc. Natl Acad. Sci. USA 92, 4562-4566.
139. Sgonc, R., Fuerhapter, C., Boeck, G., et al. (1998) "Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha", Int. Arch. Allergy Immunol. 117, 209-214.
140. von Marschall, Z., Scholz, A., Cramer, T., Schäfer, G., Schirner, M., Öberg, K., et al. (2003) "Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis", J. Natl Cancer Inst. 95, 437-448.
141. Kerbel, R.S. and Kamen, B.A. (2004) "The anti-angiogenic basis of metronomic chemotherapy", Nat. Rev. Cancer 4, 423-436.
142. Browder, T., Butterfield, C.E., Kraling, B.M., et al. (2000) "Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer", Cancer Res. 60, 1878-1886.
143. Klement, G., Huang, P., Mayer, B., et al. (2002) "Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts", Clin. Cancer Res. 8, 221-232.
144. Kakeji, Y. and Teicher, B.A. (1997) "Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents", Invest. New Drugs 15(1), 39-48.
145. Buckstein, R., Crump, M., Baruchel, S., et al. (2003) "High dose celecoxib and low dose cyclophosphamide for relapsed aggressive histology NHL", Proc. Am. Soc. Clin. Oncol. 206(22), 827a.
146. Gately, S. and Li, W.W. (2004) "Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy", Semin. Oncol. 31(2 Suppl 7), 2-11.
147. Schirner, M. (2000) "Antiangiogenic chemotherapeutic agents", Cancer Metastasis Rev. 19, 67-73.
148. Belotti, D., Vergani, V., Drudis, T, et al. (1996) "The microtubule-affecting drug paclitaxel has antiangiogenic activity", Clin. Cancer Res. 2, 1843-1849.
149. Wang, J., Lou, P., Lesniewski, R., et al. (2003) "Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly", Anticancer Drugs 14, 13-19.
150. Fennelly, D., Aghajanian, C., Shapiro, F., et al. (1997) "Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer", Clin. Oncol. 1, 187-192.
151. Boruta, D.M., 2nd, Fowler, W.C., Jr., Gehrig, P.A., et al. (2003) "Weekly paclitaxel infusion as salvage therapy in ovarian cancer", Cancer Invest. 5, 675-681.